Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG1827 in Advanced Solid Tumors
NCT06076291Phase 1Completed
- Sponsor
- Shangjian Bio
- Start
- Sep 2023
- Primary completion
- Mar 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SG1827 in solid tumor, sponsored by Shangjian Bio. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 1 year and Maximum Tolerated Dose / Recommended Phase 2 Dose at 1 year. Started Sep 2023; status: completed.
02
Drugs
SG1827
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06076291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06076291.